Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Yimitasvir in Renal Impairment vs Normal Function
NCT04565171Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Apr 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of yimitasvir in chronic hepatitis C (CHC) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Area Under the Plasma Concentration-Time Curve and Maximum Plasma Concentration. Started Apr 2021; status: completed.
02
Drugs
yimitasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT04565171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565171.